Dr Jane Lane

2023

• Fang, Z., Zeng, J. J., Yang, Y., Ruge, F., Lane, J., Hargest, R. and Jiang, W. 2023. Expression of ALCAM in clinical colon cancer and relationship with patients' treatment responses. In Vivo 37(3), pp. 1117-1128.
• Hao, C., Lane, J. and Jiang, W. G. 2023. Osteopontin and cancer: insights into its role in drug resistance. Biomedicines 11(1), article number: 197. (10.3390/biomedicines11010197)

2021

• Bosanquet, D. C. et al. 2021. Sensitivity of the wound edge gene signature "WD14" in responding to clinical change: a longitudinal cohort study. International Journal of Lower Extremity Wounds (10.1177/15347346211056786)
• Hao, C., Cui, Y., Lane, J., Jia, S., Ji, J. and Jiang, W. G. 2021. Distinctive prognostic value and cellular functions of osteopontin splice variants in human gastric cancer. Cells 10(7), article number: 1820. (10.3390/cells10071820)
• Cui, Y., Li, L., Li, Z., Yin, J., Lane, J., Ji, J. and Jiang, W. G. 2021. Dual effects of targeting S100A11 on suppressing cellular metastatic properties and sensitizing drug response in gastric cancer. Cancer Cell International 21(1), article number: 243. (10.1186/s12935-021-01949-1)
• Cui, Y., Li, Z., Cao, J., Lane, J., Birkin, E., Dong, X. and Jiang, W. G. 2021. The G4 resolvase DHX36 possesses a prognosis significance and exerts tumour suppressing function through multiple causal regulations in non-small cell lung cancer. Frontiers in Oncology 11, article number: 655757. (10.3389/fonc.2021.655757)
• Cui, Y., Hunt, A., Li, Z., Birkin, E., Lane, J., Ruge, F. and Jiang, W. G. 2021. Lead DEAD/H box helicase biomarkers with the therapeutic potential identified by integrated bioinformatic approaches in lung cancer. Computational and Structural Biotechnology Journal 19, pp. 261-278. (10.1016/j.csbj.2020.12.007)

2020

• Cong, Y. et al. 2020. Calcium-binding protein S100P promotes tumor progression but enhances chemosensitivity in breast cancer. Frontiers in Oncology 10, article number: 566302. (10.3389/fonc.2020.566302)

2019

• Bosanquet, D. C., Sanders, A. J., Ruge, F., Lane, J., Morris, C. A., Jiang, W. G. and Harding, K. G. 2019. Development and validation of a gene expression test to identify hard-to-heal chronic venous leg ulcers. British Journal of Surgery 106(8), pp. 1035-1042. (10.1002/bjs.11161)

2017

• Owen, S. et al. 2017. The clinical and biological implications of the focal adhesion kinase pathway in ShenLingLan mediated suppression of cellular migration of ovarian cancer cells. Journal of Cancer Research & Therapy 5, pp. 24-31. (10.14312/2052-4994.2017-5)

2016

• Flamini, V., Jiang, W. G., Lane, J. and Cui, Y. 2016. Significance and therapeutic implications of endothelial progenitorcells in angiogenic-mediated tumour metastasis. Critical Reviews in Oncology/Hematology 100, pp. 177-189. (10.1016/j.critrevonc.2016.02.010)
• Jiang, W. G. et al. 2016. Effects of YangZheng XiaoJi on the migration and growth of lung cancer cells, by targeting the Hepatocyte Growth Factor Receptor-Epidermal Growth Factor Receptor (HGFR-EGFR) transactivation [Abstract]. European Journal of Cancer 51(S3), pp. S642-S642., article number: 3117. (10.1016/S0959-8049(16)31758-0)

2015

• Jiang, W. G. et al. 2015. 3117 Effects of YangZheng XiaoJi on the migration and growth of lung cancer cells, by targeting the Hepatocyte Growth Factor Receptor-Epidermal Growth Factor Receptor (HGFR-EGFR) transactivation. European Journal of Cancer 51(Supp 1), pp. S642. (10.1016/S0959-8049(16)31758-0)
• Jiang, W. G. et al. 2015. YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells. Journal of Translational Medicine 13, article number: 280. (10.1186/s12967-015-0639-1)
• Jiang, W. et al. 2015. Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth.. Anticancer Research 35(3), pp. 1321-1331.

2014

• Jiang, W. G., Sanders, A. J., Cox, E. D., Bosanquet, D. C., Ruge, F., Lane, J. and Harding, K. G. 2014. A gene expression signature that predicted the clinical outcome of chronic wounds [Abstract]. Wound Repair and Regeneration 22(5), pp. A84-A84. (10.1111/wrr.12218)
• Ye, L., Sun, P., Sanders, A. J., Martin, T. A., Lane, J., Mason, M. D. and Jiang, W. G. 2014. Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour-related angiogenesis. International Journal of Oncology 45(4), pp. 1565-1573. (10.3892/ijo.2014.2533)
• Lane, J., Martin, T. A., Weeks, H. P. and Jiang, W. G. 2014. Structure and role of WASP and WAVE in Rho GTPase signalling in cancer. Cancer Genomics and Proteomics 11(3), pp. 155-165.

2013

• Martin, T. A., Lane, J., Harrison, G. M. and Jiang, W. G. 2013. The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. PLoS ONE 8(12), article number: e82696. (10.1371/journal.pone.0082696)
• Martin, T. A., Lane, J., Ozupek, H. and Jiang, W. G. 2013. Claudin-20 promotes an aggressive phenotype in human breast cancer cells. Tissue Barriers 1(3), article number: e26518. (10.4161/tisb.26518)
• Martin, T. A., Ye, L., Sanders, A. J., Lane, J. and Jiang, W. G. 2013. Cancer invasion and metastasis: molecular and cellular perspective. In: Jandial, R. ed. Metastatic Cancer Clinical and Biological Perspectives. Austin, TX: Landes Bioscience, pp. 135-168.

2012

• Lane, J. and Jiang, W. G. 2012. Epithelial-mesenchymal transition and the use of ECIS. In: Jiang, W. G. ed. Electric Cell-Substrate Impedance Sensing and Cancer Metastasis., Vol. 17. Cancer Metastasis - Biology and Treatment Dordrecht: Springer Science+Business Media, pp. 71-84., (10.1007/978-94-007-4927-6_5)

2011

• Lane, J., Martin, T. A. and Jiang, W. G. 2011. HGF and rhoGTPases in cancer cell motility. Current Signal Transduction Therapy 6(2), pp. 173-179. (10.2174/157436211795660052)

2010

• Lane, J., Martin, T. A. and Jiang, W. G. 2010. Targeting RhoC by way of ribozyme trangene in human breast cancer cells and its impact on cancer invasion. World Journal of Oncology 1(1), pp. 7-13. (10.4021/wjon2010.01.1202)
• Lane, J., Martin, T., McGuigan, C., Mason, M. and Jiang, W. 2010. The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. Journal of Experimental Therapeutics and Oncology 8(3), pp. 203-210.

2008

• Lane, J., Martin, T. A., Mansel, R. E. and Jiang, W. G. 2008. The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. International Seminars in Surgical Oncology 5(1), article number: 23. (10.1186/1477-7800-5-23)
• Sanders, A. J., Parr, C., Martin, T. A., Lane, J., Mason, M. D. and Jiang, W. G. 2008. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. Journal of Cellular Physiology 216(3), pp. 780-789. (10.1002/jcp.21460)
• Lane, J., Martin, T. A., Watkins, G., Mansel, R. E. and Jiang, W. G. 2008. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. International Journal of Oncology 33(3), pp. 585-593. (10.3892/ijo_00000044)

2007

• Parr, C. et al. 2007. Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clinical Cancer Research 13(12), pp. 3568-3576. (10.1158/1078-0432.CCR-06-2357)

2006

• Lane, J., Martin, T. A. and Jiang, W. G. 2006. Novel protein binding partners for Rho-associated serine-threonine protein kinases (ROCKS) in breast cancer cells [Abstract]. Breast Cancer Research and Treatment 100(1 Supp), pp. S298-S298., article number: 6127.
• Sanders, A. J., Parr, C., Davies, G., Martin, T. A., Lane, J., Mason, M. D. and Jiang, W. G. 2006. Genetic reduction of matriptase-1 expressionj is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. Journal of Experimental Therapeautics and Oncology 6(1), pp. 39-48.
• Sanders, A. J., Parr, C., Davies, G., Martin, T. A., Lane, J., Mason, M. D. and Jiang, W. G. 2006. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. Journal of Experimental Therapeutics and Oncology 6(1), pp. 39-48.

2005

• Lane, J., Martin, T. and Jiang, W. G. 2005. Targeting Rho-C by way of ribozyme transgene in human breast cancer cells and its impact on cancer invasion. Breast Cancer Research and Treatment 94(1), pp. S188-S189., article number: 4068. (10.1007/s10549-005-1234-6)
• Lane, J., Martin, T. A. and Jiang, W. G. 2005. ROCK inhibitor Y-27632 suppresses the effect of HGF in human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 94(1 Supp), pp. S193-S194., article number: 4082.
• Martin, T. A., Watkins, G., Lane, J. and Jiang, W. G. 2005. Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology 46(4), pp. 422-430. (10.1111/j.1365-2559.2005.02104.x)

2003

• Jiang, W. G., Watkins, G., Lane, J., Cunnick, G. H., Douglas-Jones, A. G., Mokbel, K. and Mansel, R. E. 2003. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clinical cancer research 9, pp. 6432-40.
• Jiang, W. G. et al. 2003. Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clinical Cancer Research 9(11), pp. 4274-4281.
• Davies, G. et al. 2003. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesisin vivo. International Journal of Cancer 106(3), pp. 348-354. (10.1002/ijc.11220)
• Lane, J., Mansel, R. E. and Jiang, W. G. 2003. Expression of human delta-6-desaturase is associated with aggressiveness of human breast cancer. International Journal of Molecular Medicine 12(2), pp. 253-257. (10.3892/ijmm.12.2.253)
• Martin, T. A. et al. 2003. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24(8), pp. 1317-1323. (10.1093/carcin/bgg072)

2002

• Gomez, K., Lane, J., Cunnick, G., Grimshaw, D., Jiang, W. G. and Mansel, R. E. 2002. From PCR to RCA: a surgical trainee's guide to the techniques of genetic amplification. European Journal of Surgical Oncology (EJSO) 28(5), pp. 554-556. (10.1053/ejso.2002.1288)

2001

• Jiang, W. G., Grimshaw, A. D., Lane, J., Martin, T. A., Abounader, R., Laterra, J. and Mansel, R. E. 2001. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clinical Cancer Research 7, pp. 2555-2562.